Hepatocellular carcinoma: signaling pathways and therapeutic advances

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: Feb. 6, 2025

Abstract Liver cancer represents a major global health concern, with projections indicating that the number of new cases could surpass 1 million annually by 2025. Hepatocellular carcinoma (HCC) constitutes around 90% liver and is primarily linked to factors incluidng aflatoxin, hepatitis B (HBV) C (HCV), metabolic disorders. There are no obvious symptoms in early stage HCC, which often leads delays diagnosis. Therefore, HCC patients usually present tumors advanced incurable stages. Several signaling pathways dis-regulated cause uncontrolled cell propagation, metastasis, recurrence HCC. Beyond frequently altered therapeutically targeted receptor tyrosine kinase (RTK) involved differentiation, telomere regulation, epigenetic modification stress response also provide therapeutic potential. Investigating key their inhibitors pivotal for achieving advancements management At present, primary approaches (TKI), immune checkpoint (ICI), combination regimens. New trials investigating therapies involving ICIs TKIs or anti-VEGF (endothelial growth factor) therapies, as well combinations two immunotherapy The outcomes these expected revolutionize across all Here, we here comprehensive review cellular pathways, potential, evidence derived from late-stage clinical discuss concepts underlying earlier trials, biomarker identification, development more effective therapeutics

Language: Английский

---

Eriodictyol 5-O-methyl ether inhibits prostate cancer progression through targeting STAT3 signaling and inducing apoptosis and paraptosis

Archives of Biochemistry and Biophysics, Journal Year: 2025, Volume and Issue: 766, P. 110331 - 110331

Published: Feb. 7, 2025

Language: Английский

---

Comprehensive review of leonurine: harnessing its therapeutic potential for chronic diseases

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Language: Английский

---

Brassinin alleviates cancer cachexia by suppressing diverse inflammatory mechanisms in mice

MedComm, Journal Year: 2024, Volume and Issue: 5(6)

Published: May 28, 2024

Abstract Cancer cachexia is a multifactorial condition that contributes to the death of about 20% cancer patients. It has potential cause weight loss, reduction in muscle mass, and loss fat tissue, significantly lowering quality life. Currently, there are no approved drugs for cachexia. Here, we have explored possible impact brassinin (BSN) on under vitro vivo settings. After differentiation, C2C12 3T3‐L1 cells were incubated with colorectal carcinoma conditioned media or BSN. For preclinical studies, mice injected HT‐29 followed by intraperitoneal administration BSN, adipose tissues evaluated Western blotting hematoxylin eosin staining. BSN effectively suppressed atrophy down‐regulating levels Muscle RING‐finger protein‐1 Atrogin‐1, while also increasing expression myosin heavy chain cachexia‐induced‐C2C12 myotubes. The induction adipogenesis prevented adipocyte cachexia‐induced adipocytes. We noted disrupted interaction between COX‐2 signaling transducer activator transcription 3 (STAT3) promoter, leading down‐regulation STAT3 activation. Moreover, it was found inhibited demonstrated anti‐cachexic effects. Overall, our observations indicate can attenuate through diverse mechanisms.

Language: Английский

---

TMP: A dual modulator of apoptosis and autophagy via SHP-1 regulation in hepatocellular carcinoma

Life Sciences, Journal Year: 2024, Volume and Issue: unknown, P. 123316 - 123316

Published: Dec. 1, 2024

Language: Английский

---